Latest News
USPSTF lung cancer screening recommendations in high-risk Medicare beneficiaries is cost effective
Questions regarding effectiveness, infrastructure and cost effectiveness of low-dose computed tomography (CT) screening of those at high risk for lung cancer have now been answered. Medicare should rapidly provide full national coverage for these exams. An actuarial cost-benefit analysis by Milliman, Inc., published in the August issue of American Health and Drug Benefits, shows that use of United States Preventive Services Task Force (USPSTF) lung cancer screening recommendations in high-risk Medicare beneficiaries is cost effective. …Read More